Valneva commences manufacturing of its inactivated, adjuvanted COVID-19 vaccine, completes Phase 1/2 study recruitment

Valneva SE, a specialty vaccine company focused on prevention of infectious diseases with significant unmet medical need, today announced it has commenced production of its inactivated, adjuvanted COVID-19 vaccine candidate in parallel to the ongoing clinical studies, in order to optimize the timeline for potential deliveries of the vaccine. The Phase 1/2 clinical study is now fully enrolled and is expected to report initial results in April 2021.

from Breaking World Pharma News https://ift.tt/3r3iOPE